Collegium Pharmaceutical
COLL · Pharmaceuticals
$22.96
2.3%Corcept Therapeutics
CORT · Pharmaceuticals
$85.86
20.1%The short version
- Collegium Pharmaceutical is the larger business, with $781M of revenue in fiscal 2025 against $761M for Corcept Therapeutics.
- Collegium Pharmaceutical grew revenue faster (23.6%, against 12.8%).
- Collegium Pharmaceutical kept more of each dollar of sales as operating profit (23.0% operating margin, against 5.9% operating margin).
- Collegium Pharmaceutical turned more of its sales into free cash flow (42.0% FCF margin, against 18.6% FCF margin).
- Collegium Pharmaceutical earned a higher return on the capital invested in it (53.4%, against 15.7%).
| Latest fiscal year | COLL · FY25 | CORT · FY25 |
|---|---|---|
| Size | ||
| Market cap | $746M | $10.2B |
| Revenue | $781M | $761M |
| Free cash flow | $328M | $142M |
| Net income | $62.9M | $99.7M |
| Growth | ||
| Revenue growth | 23.6% | 12.8% |
| 5-year growth | 20.3% | 16.6% |
| Share count change | −1.8% | 5.7% |
| Profitability | ||
| Gross margin | 59.4% | 98.3% |
| Operating margin | 23.0% | 5.9% |
| Net margin | 8.1% | 13.1% |
| FCF margin | 42.0% | 18.6% |
| Return on capital | 53.4% | 15.7% |
| Return on equity | 23.7% | 15.0% |
| Balance sheet | ||
| Net debt | −$149M | −$372M |
| Net debt / EBITDA | −0.4x | −8.1x |
| Dividends and buybacks | $25.1M | $173M |
| Valuation & quality | ||
| P/E | 18.5x | — |
| Piotroski F-score | 6 | 3 |
FY16
COLL $1.7M
CORT $81.3M
FY17
COLL $28.5M
CORT $159M
FY18
COLL $280M
CORT $251M
FY19
COLL $297M
CORT $307M
FY20
COLL $310M
CORT $354M
FY21
COLL $277M
CORT $366M
FY22
COLL $464M
CORT $402M
FY23
COLL $567M
CORT $482M
FY24
COLL $631M
CORT $675M
FY25
COLL $781M
CORT $761M
COLL
CORT
FY16
COLL −5,498.7%
CORT 12.5%
FY17
COLL −265.0%
CORT 33.2%
FY18
COLL −7.4%
CORT 35.6%
FY19
COLL −8.0%
CORT 36.4%
FY20
COLL 18.1%
CORT 36.2%
FY21
COLL 6.4%
CORT 34.0%
FY22
COLL 7.2%
CORT 28.0%
FY23
COLL 29.5%
CORT 22.2%
FY24
COLL 26.9%
CORT 20.3%
FY25
COLL 23.0%
CORT 5.9%
COLL
CORT
FY16
COLL −$75.5M
CORT $18.2M
FY17
COLL −$68.0M
CORT $60.5M
FY18
COLL $164M
CORT $115M
FY19
COLL $21.3M
CORT $135M
FY20
COLL $88.4M
CORT $151M
FY21
COLL $102M
CORT $167M
FY22
COLL $123M
CORT $120M
FY23
COLL $274M
CORT $127M
FY24
COLL $203M
CORT $196M
FY25
COLL $328M
CORT $142M
COLL
CORT
FY16
COLL —
CORT —
FY17
COLL —
CORT 99.0%
FY18
COLL —
CORT 85.5%
FY19
COLL —
CORT 109.6%
FY20
COLL —
CORT 116.1%
FY21
COLL 10.4%
CORT 95.4%
FY22
COLL 16.5%
CORT 88.4%
FY23
COLL 68.7%
CORT 87.6%
FY24
COLL 53.0%
CORT 55.1%
FY25
COLL 53.4%
CORT 15.7%
COLL
CORT
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.